Boston Scientific reported third quarter 2026 net sales of $5.138 billion, up 1.5% year-over-year, and adjusted EPS of $0.73, both exceeding consensus estimates. However, the results and outlook were significantly impacted by an August 2026 cybersecurity incident that disrupted operations and procedural volumes across key business segments.
Key Highlights
- Cardiovascular organic revenue growth of 1.9% missed the consensus estimate of 15.2% as the cybersecurity event hampered commercial momentum.
- MedSurg organic growth was limited to 0.7%, with strong 13.0% growth in Neuromodulation offset by declines in Urology (-3.1%) and Endoscopy (-0.6%).
- The company projected a fourth quarter net sales decline of (3.0)% to (1.0)% as recovery efforts from the cyber incident continue.
- Full-year 2026 guidance was updated to reflect net sales growth of 4.25% and adjusted EPS between $3.16 and $3.18.